



AMERICAN SOCIETY OF PEDIATRIC HEMATOLOGY/ONCOLOGY
23RD ANNUAL MEETING

April 7–10, 2010 Montréal, Québec, Canada
Fairmont the Queen Elizabeth Hotel

The most comprehensive and focused educational opportunity for pediatric hematologists/oncologists, the ASPHO 23rd Annual Meeting provides a unique opportunity to network and collaborate with fellow subspecialists in pediatric hematology/oncology. The annual meeting will present current research data on causes, diagnoses, and management of hematology/oncology problems in children and will apply data to clinical practice.

The 2010 meeting will feature

- ◆ an expanded Young Investigator program
- ◆ seven new workshops
- ◆ in-depth symposia on cancer survivorship and sickle cell disease research in the 21st century
- ◆ a special session on your role as medical educator
- ◆ two author-attended poster sessions
- ◆ products and services from more than 40 exhibiting companies
- ◆ original science abstract platform sessions
- ◆ a workshop geared toward career development and increasing diversity in hematology/oncology
- ◆ a special session on maintenance of certification.

Objectives

- ◆ Comprehend new information in pediatric hematology/oncology, including the latest in basic and clinical research.
- ◆ Apply knowledge gained in all areas of pediatric hematology/oncology investigation and practice.
- ◆ Assemble a network of professional colleagues with whom to solve problems, share experiences, and provide mutual professional support.

Continuing Medical Education Credit

The ASPHO 23rd Annual Meeting will offer CME credit. Credit will be awarded for those sessions attended and evaluated. A certificate will be issued upon receipt of submission of the evaluation form.

ASPHO is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ASPHO designates this education activity for a maximum of 26.75 **AMA PRA Category 1 Credits™**. Physicians should claim credit commensurate with the extent of their participation in the activity.

Disclosure

It is the policy of ASPHO that the planners and faculty disclose the existence of any significant financial interest or other relationships they may have with the manufacturer(s) of any commercial product(s) or services relating to the topics presented in the educational activity. ASPHO requires disclosure of the intent to discuss unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose. It is the responsibility of the Program Committee to review potential conflicts of interest as submitted in the disclosure form and resolve such conflicts. Resolving the conflict ensures that the content of the activity is aligned with the interests of the public. Detailed disclosure information will be published in course materials. Learners will also be informed when no relevant financial relationships exist.

Disclaimer

The material presented in these activities represents the opinion of the speakers and not necessarily the views of ASPHO.



Remember, you will need a passport to travel to Montréal!





Schedule at a Glance

Wednesday, April 7, 2010

2–5:30 pm

In-Depth Symposia

(IDS1) Cancer Survivorship

(IDS2) Sickle Cell Disease Research in the 21st Century

5:45–7:15 pm

Concurrent Workshops

(W01) Quality Improvement in Pediatric Hematology/Oncology: A Practical Approach

(W02) Pediatric Thrombosis: It Is Not Only About Thrombophilia

7:30–9 pm

Corporate Forum Dinner Symposium*

Contemporary Challenges in the Diagnosis and Management of von Willebrand's Disease

Thursday, April 8, 2010

7–8:30 am

Workshop

(W03) Young Investigator Workshop 

Special Session

(L01) Maintenance of Certification: Answers to Your Questions

8:45–10:45 am

Presidential Symposium

(S01) Medical Education in the Current Era: Can This Patient Be Saved?

11:15 am–12:15 pm

Concurrent Platform Sessions I

12:30–2 pm

One-on-One Young Investigator Career Workshop Lunch

(Advance registration is required.)

Corporate Forum Luncheon Symposium*

Perspectives in Hemophilia: Clinical Challenges and Current Issues in Managing Patients with Inhibitors

2:15–4:15 pm

Symposia

(S02) Practical Care of the Patient with Fanconi Anemia

(S03) New Therapies for Sarcomas—What Basic Science Has to Offer

4:45–5:45 pm

Plenary Platform Session

Young Investigator Award

Presentations 

5:45–6:45 pm

Author-Attended Poster Session A

5:45–7:30 pm

Grand Opening Reception with Exhibits and Posters

7:30–9 pm

Corporate Forum Dinner Symposium*

Optimizing Chelation Therapy for Pediatric Iron Overload: Emerging Strategies

7:30–9 pm

Training Program Directors' Meeting

Friday, April 9, 2010

7–8:30 am

Corporate Forum Breakfast Symposium*

8:45–10:45 am

Symposia

(S04) Novel Developmental Therapeutic Approaches in Pediatric Oncology: The Future of Drug Delivery to Tumors

(S05) "When in Québec, Do What the Québécois Do!" —Québec Platelet Disorder, Giant Platelets, and Other Functional Platelet Abnormalities

10:45–11:15 am

Break with Exhibits and Posters

11:15 am–12:15 pm

Concurrent Platform Sessions II

12:30–1:45 pm

Author-Attended Poster Session B

12:30–1:45 pm

Break with Exhibits and Posters

1:45–3:45 pm

Symposia

(S06) Pediatric Oncology in Developing Countries: How Can We Collaborate?

(S07) Functional Genomics

3:45–4:15 pm

Break with Exhibits and Posters

4:15–5:45 pm

Concurrent Workshops

(W04) Improving Outcomes for High-Risk ALL: Translating New Discoveries into Clinical Care

(W05) Management of Very Young Children with Brain Tumors

6–7:30 pm

Business Meeting and Award Presentations

◆ President's Remarks

◆ Frank A. Oski Memorial Lecture

◆ Distinguished Career Award

7:45–8:15 pm

Award Reception

Saturday, April 10, 2010

7–8:30 am

Concurrent Workshops

(W06) Staging, Grouping, and Risk Assignment for Childhood Rhabdomyosarcoma

(W07) Career Development and Increasing Diversity in Pediatric Hematology/Oncology

8:45–10:45 am

Symposia

(S08) Immunotherapy for Pediatric Cancer

(S09) Thrombosis in Patients with Cancer

11:15 am–1:15 pm

Symposia

(S10) Selecting Your Path and Taking the Critical First Steps Toward a Successful Career 

(S11) Biology of ALL

*For more information on corporate forum symposia, see page 12.

Educational Program | Wednesday, April 7, 2010

2–5:30 pm

In-Depth Symposia

(IDS1) Cancer Survivorship

Moderators: Jacqueline N. Casillas, MD MSHS; Debra L. Friedman, MD MS

There are now approximately 300,000 childhood cancer survivors in the United States. Childhood cancer survivors are at risk for late effects and chronic health problems as a result of primary chemotherapy, radiation, and surgery. The late effects of cancer treatment can include heart and lung dysfunction, secondary cancers, and psychosocial sequelae. The late effects occur several years to decades after the previous cancer treatment, resulting in a high burden of chronic disease during young adult years. It is, therefore, critical for cancer survivors to receive long-term follow-up care to screen for late effects during their pediatric, adolescent, and young adult years. Yet, the majority of childhood cancer survivors are not getting appropriate long-term follow-up care. National cooperative group efforts have provided best practice recommendations to improve the quality of care childhood cancer survivors receive.

Cancer Survivorship Care Planning

Noreen M. Aziz, MD PhD MPH; Melissa M. Hudson, MD

Screening for Medical Late Effects of Childhood Cancer Treatment

Debra L. Friedman, MD MS; Smita Bhatia, MD MPH

Optimizing Psychological Well-Being for Childhood Cancer Survivors and Their Families

Christopher J. Recklitis, PhD MPH

Assessing for Transition Readiness for Adolescent and Young Adult Childhood Cancer Survivors

Lisa A. Schwartz, PhD; Anna T. Meadows, MD

(IDS2) Sickle Cell Disease Research in the 21st Century

Moderator: Zora R. Rogers, MD

Sickle cell disease (SCD) is the most common hematologic disorder treated by pediatric hematologists/oncologists, usually with the same modalities (analgesics and hydration) employed for many decades. Physicians have often questioned how the same single amino acid substitution can give rise to such variation in disease burden amongst patients. The significant advances made in the past decade in our understanding of the basic pathophysiology of SCD are now being translated into improvements in clinical management. Speakers will discuss current survival and risk prediction, nitric oxide biology and the hemolysis phenotype, stroke risk and management, available management strategies with hydroxyurea, chronic transfusion, and stem cell transplant. The future of gene therapy for SCD will be reviewed and National Institutes of Health (NIH) scientific staff will discuss how the realignment of their Sickle Cell Research Portfolio will support these new areas of research.

Realignment of the NIH Sickle Cell Research Portfolio: 2010 and Beyond

W. Keith Hoots, MD

Current Assessments of Survival and Risk Prediction in Sickle Cell Disease

Charles T. Quinn, MD MS

Nitric Oxide Biology and Hemolysis Phenotype in Sickle Cell Disease

Gregory J. Kato, MD

Stroke and Silent Stroke in Sickle Cell Disease: Prevention, Consequences, and Management

James F. Casella, MD

Sickle Cell Disease Modifying Therapies: Hydroxyurea and Chronic Transfusion

Zora R. Rogers, MD

Sickle Cell Disease Modifying Therapies: Stem Cell Transplant and Gene Therapy

Punam Malik, MD

5:45–7:15 pm

Concurrent Workshops

(W01) Quality Improvement in Pediatric Hematology/Oncology: A Practical Approach

Moderator: Amy L. Billett, MD

Quality improvement (QI) is a necessary function in all healthcare programs, including pediatric hematology/oncology. QI is necessary to provide excellent care and meet requirements from payers, the Joint Commission, the American Board of Pediatrics Maintenance of Certification, the Accreditation Council for Graduate Medical Education training programs, and other organizations or governmental bodies. Most programs develop their own projects and approaches to QI but may or may not have specific expertise in this area. Best practices can be defined for QI in general, but there are no such guidelines specifically for pediatric hematology/oncology. This workshop will provide information about basic principles of QI and relevant regulatory guidelines. Specific examples of current national and local pediatric hematology/oncology QI projects will be presented.

Background and Updates on Quality Improvement Methodology

Amy L. Billett, MD

Reducing Length of Stay in Sickle Cell Disease

Brigitta U. Mueller, MD CPE MHCM

Reducing Time to First Antibiotics in Fever and Neutropenia

Randy A. Hock, MD PhD CPE MMM

(W02) Pediatric Thrombosis: It Is Not Only About Thrombophilia

Moderator: Leonardo R. Brandao, MD

Although the literature on thrombosis in children focuses on cases related to underlying systemic conditions, the presence of central lines, and inherited thrombophilia conditions, little information is available on children with an anatomical abnormality. Such cases require a multidisciplinary approach to ensure their appropriate diagnosis, therapeutic plan, and follow-up.

Mostly in adolescents, the cases of thrombosis due to anatomic variants include (a) exercise-induced upper-extremity deep vein thrombosis (Paget-Schroetter syndrome); (b) iliac vein compression syndrome (May-Thurner syndrome); and (c) inferior vena cava abnormality. Although considered rare, delay on these diagnoses and treatments contribute to severe long-term complications.

No current algorithms are available regarding diagnostic or therapeutic options. Best practices include imaging (ultrasound, CTV, MRV, or venogram) without therapy, catheter-directed thrombolysis with or without stent placement, long-term anticoagulation, or surgery (only in severe cases, given the complication rates).

Clinical Aspects of Anatomical Anomalies in Pediatric Thrombosis

Leslie Raffini, MD MSCE

Interventional Aspects and Treatment of Thrombosis

Michael J. Temple, MD

Surgical Approach to Upper Anatomic Extremity Anomalies in Pediatric Thromboses

Vern M. Campbell, MD FACS FRCSC

7:30–9 pm

Corporate Forum Dinner Symposium

Contemporary Challenges in the Diagnosis and Management of von Willebrand's Disease

Robert R. Montgomery, MD; Augusto B. Federici, MD; Andra H. James, MD; Craig M. Kessler, MD

Preregistration is required for this session. For further information, please see page 12.

Educational Program | Thursday, April 8, 2010

7–8:30 am

(W03) Young Investigator Workshop

Moderators: Caroline A. Hastings, MD; Douglas K. Graham, MD PhD

As pediatric hematologists/oncologists, we are often called upon to lead difficult discussions with our patients and their families, such as delivering bad news and discussing end-of-life care. Poor preparation for these situations can lead to physician stress and burnout and poor patient satisfaction. Part of this session will discuss how these skills are currently being taught in fellowship programs, review pertinent literature on the subject, and provide participants with some simple pointers to improve their skills. Also, many institutions have established mentoring programs. Gender, generational differences, and changing faculty demographics contribute to gaps and inadequacies in these programs where success is vital to the academic vitality of an institution. This workshop will review different novel models and approaches to mentorship, including group and mosaic mentorship. We will further review common pitfalls and mistakes in mentorship relationships and discuss strategies to maximize academic success.

Simple Techniques

Timothy P. Garrington, MD

Mentorship: Common Inadequacies and Novel Strategies

Naomi L. C. Luban, MD

Unique Challenges Faced by Fellows/Junior Faculty

Emily Riehm Meier, MD

Special Session

(L01) Maintenance of Certification: Answers to Your Questions

Moderator: A. Kim Ritchey, MD

This session is designed to familiarize the membership with the new requirements for Maintenance of Certification (MOC) of the American Board of Pediatrics. Drs. Paul V. Miles and H. James Brown from the American Board of Pediatrics will discuss the genesis of MOC, the importance of the process, and the practical aspects of the program. Quality improvement in action—the pediatric hematology/oncology nosocomial catheter-associated blood stream infection collaborative—will be discussed by Dr. Amy L. Billett. Finally, a panel including the speakers and former subboard chair Dr. Dana C. Matthews, will answer questions from the membership.

Overview of Maintenance of Certification

Paul V. Miles, MD

Practical Aspects of MOC for the Pediatric Hematologist/Oncologist

H. James Brown, MD

Quality Improvement in Action: The Pediatric Hematology/Oncology Catheter-Associated Blood Stream Infection Collaborative

Amy L. Billett, MD

Questions from the Audience

Paul V. Miles, MD; H. James Brown, MD; Amy L. Billett, MD; Dana C. Matthews, MD

8:45–10:45 am

Presidential Symposium

(S01) Medical Education in the Current Era: Can This Patient Be Saved?

Holcombe E. Grier, MD; Lewis First, MD MS; Jennifer Kesselheim, MD MEd

Although ASPHO's members are diverse in many ways, they share a common dedication to a career in which both teaching and learning are essential components. The hematologist/oncologist may be asked to teach other faculty members, trainees, or professionals from other disciplines such as nursing. In addition, clinical duties include a responsibility to educate patients and their family members. How can we effectively and efficiently teach so many different parties, especially when the time allowed for education is always inadequate? This symposium will explore adult learning principles and demonstrate how a more thorough understanding of the manner in which adults learn can greatly assist us as we teach. We will also explore the challenge of providing feedback to learners, a process that may feel awkward at times, but is crucial to the education process.

This symposium is supported by the St. Baldrick's Foundation.

11:15 am–12:15 pm

Concurrent Platform Sessions I

12:30–2 pm

One-on-One Young Investigator Career Workshop Lunch 

Moderators: Douglas K. Graham, MD PhD; Caroline A. Hastings, MD

Fellows and young investigators (YIs) will have an opportunity to meet with a leader in the field of pediatric hematology/oncology. One or two experts in the following fields will be available for the career discussions: clinical research (hematology), clinical research (oncology), basic science/translational research, health services/late effects, and clinician/educator. A special interest table will be available for issues specific to foreign medical graduates. The purpose of the luncheon is to allow fellows and junior faculty to discuss one-on-one issues or questions related to career development in a small group setting. One or two discussion leaders will be placed at each luncheon table. After 30 minutes of discussion, the YI participants will be invited to consider switching to a different table for further discussion.

Advance registration and \$15 fee required.

(LCH) Clinical Research: Hematology

Thomas C. Abshire, MD; Jorge DiPaola, MD

(LCO) Clinical Research: Oncology

Kelly Maloney, MD; A. Kim Ritchey, MD

(LBT) Basic Science/Translational Research

John M. Maris, MD; Patrick A. Zweidler-McKay, MD PhD

(LCS) Health Services/Late Effects

Joseph P. Neglia, MD MPH

(LCE) Clinician/Educator

Elliott P. Vichinsky, MD

(FMG) Foreign Medical Graduates

Sarah R. Vaiselbuh, MD; Ram Kalpathi, MD

Corporate Forum Luncheon Symposium

Perspectives in Hemophilia: Clinical Challenges and Current Issues in Managing Patients with Inhibitors

Amy D. Shapiro, MD; Victor S. Blanchette, MD FRCP(C); Craig M. Kessler, MD

Preregistration is required for this session. For further information, please see page 12.

2:15–4:15 pm

Symposia

(S02) Practical Care of the Patient with Fanconi Anemia

Moderator: Denise M. Adams, MD

Much has been learned in the last decade about the molecular pathway that is mutated in Fanconi Anemia (FA) patients. There are multiple tests from a variety of sources available to genotype FA patients, and emerging information is becoming available about genotype/phenotype correlations. The types of malignancies for which FA patients are at increased risk have expanded. This session will provide a concise update of current understanding of the FA molecular pathway, the risk and types of cancer observed in persons with FA, modern diagnostic and prognostic testing for a patient with FA, and an overview of the 3rd edition of the new consensus document *Fanconi Anemia: Guidelines for Diagnosis and Management*.

Fanconi Anemia: What it Can Teach Us About Bone Marrow Failure and Cancer Predisposition

Blanche P. Alter, MD MPH FAAP

Diagnostic Testing for Fanconi Anemia: What Tests, How to Obtain Them, and What They Mean

David A. Williams, MD

Clinical Care: Patient Education and Genotype Prognostication

Zora R. Rogers, MD

(S03) New Therapies for Sarcomas—What Basic Science Has to Offer

Moderator: Leo Mascarenhas, MD MS

Sarcomas constitute approximately 15% of all childhood and adolescent cancers with a peak incidence in adolescents and young adults. They are treated with a multidisciplinary approach that usually utilizes surgery, chemotherapy, and radiation. This cures approximately 70% of those with localized disease. The outcome of those with metastatic or recurrent disease is dismal with less than 20% of patients achieving long-term remissions. Further, survival rates appear to have reached a plateau. Recently, rapid advancement in the basic sciences has dramatically increased our knowledge of cancer pathways and mechanisms of disease. This has led to a plethora of drugs that target various pathways. Some of these new agents have been used successfully to alter the outcome of select cancers. This symposium will draw from new discoveries in the basic sciences as well as the clinical trial experience in adult patients with sarcomas to address strategies for new therapies in children with sarcomas.

This symposium is supported by The Sarcoma Foundation.

Introduction and Outcomes of Patients with Pediatric Sarcomas

Leo Mascarenhas, MD MS

From Genetics to New Targets for the Treatment of Childhood Sarcomas

Poul Sorensen, MD PhD

Evolving Concepts on Medical Therapy for Soft Tissue Sarcomas

George D. Demetri, MD

Challenges and Opportunities for Incorporating Molecular Targeted Therapy in Pediatric Sarcoma Trials

Alberto S. Pappo, MD

4:45–5:45 pm

Plenary Platform Session

Young Investigator Award Presentations 

5:45–6:45 pm

Author-Attended Poster Session A

5:45–7:30 pm

Grand Opening Reception with Exhibits and Posters

7:30–9 pm

Corporate Forum Dinner Symposium

Optimizing Chelation Therapy for Pediatric Iron Overload: Emerging Strategies

Elliott P. Vichinsky, MD; John B. Porter, MD MA FRCP FRCPath; John C. Wood, MD PhD; Nancy F. Olivieri, MD BSC FRCPC

Preregistration is required for this session. For further information, please see page 12.

7:30–9 pm

Training Program Directors' Meeting

Educational Program | Friday, April 9, 2010

7–8:30 am

Corporate Forum Breakfast Symposium

8:45–10:45 am

Symposia

(S04) Novel Developmental Therapeutic Approaches in Pediatric Oncology: The Future of Drug Delivery to Tumors

Moderator: Daniel S. Wechsler, MD PhD

This symposium will address three cutting-edge approaches for drug delivery. *Nanotechnology*—what does it mean in relation to pediatric oncology? An overview of nanotechnology, different types of nonmaterial, potential specific applications to diagnosis, and therapy in pediatric oncology will be addressed. *Drug delivery to the central nervous system (CNS)*—new ways to deliver old and new agents to the CNS, for both brain and non-brain tumors (e.g., CNS leukemia), and challenges and opportunities to increase CNS penetration will be discussed. *Novel methods of drug/nucleic acid delivery to tumors*—a novel, ultrasound-based approach for targeting drugs/nucleic acids (genes/siRNA) to tumors will be highlighted. The approach focuses on generated microbubbles containing concentrated drug/nucleic acid injected into the circulation. An ultrasound is used to burst the bubbles, releasing the contents in only the region where a probe is directed. Implications for therapy of pediatric tumors, especially neuroblastoma, will be discussed.

Introduction and Overview

Daniel S. Wechsler, MD PhD

Nanotechnology: An Overview

Noah Federman, MD

Old and New Methods of CNS Drug Administration

Susan Blaney, MD

Ultrasound/Microbubbles-Based Delivery

Darrell J. Yamashiro, MD PhD

(S05) “When in Québec, Do What the Québécois Do!”—Québec Platelet Disorder, Giant Platelets, and Other Functional Platelet Abnormalities

Moderators: Victor S. Blanchette, MD FRCP(C); Georges E. Rivard, MD

The 2010 ASPHO Annual Meeting locale, coupled with recent research findings, inspired an appropriate focus on two uncommonly diagnosed platelet disorders: Québec Platelet Disorder and Montréal Platelet Syndrome. The former is a unique inherited bleeding disorder characterized by increased platelet-dependent fibrinolysis. The latter features spontaneous platelet aggregation and hereditary macrothrombocytopenia and is now recognized as a form of von Willebrand’s disease, type 2B. In addition to an update on these two somewhat provincial diagnoses, other important causes of giant platelets will be reviewed in terms of diagnostic considerations and recent research advances.

Another recently elucidated cause of inherited macrothrombocytopenia is mutation of the MYH9 gene encoding the nonmuscle myosin-heavy chain IIA, a cytoskeletal contractile protein expressed in platelets and many other tissues. Diagnostic and management considerations and current understanding of the molecular basis for this multisystem class of disorders will be discussed as it forms an important differential diagnosis for the more commonly recognized entity, chronic autoimmune thrombocytopenia.

Finally, despite expert opinion that qualitative platelet disorders are a common contributor to clinical bleeding, the diagnostic evaluation

of platelet function defects in pediatrics remains challenging in many aspects. Such difficulties include a lack of consensus on when platelet function testing is indicated, methodologic standardization, and the clinical utility of available tests. Platelet function assays available for clinical use will be reviewed along with evidence supporting their diagnostic and therapeutic utility and use of standardized bleeding scores to facilitate clinical assessment.

Québec Platelet Disorder, Montréal Platelet Syndrome, and Giant Platelets

Walter H. Kahr, MD PhD FRCPC

It’s Not Just About Platelets—The MYH9-Related Spectrum of Disorders

Naomi L. C. Luban, MD

Evaluation of Patients with Suspected Platelet Dysfunction

Sara J. Israels, MD

10:45–11:15 am

Break with Exhibits and Posters

11:15 am–12:15 pm

Concurrent Platform Sessions II

12:30–1:45 pm

Author-Attended Poster Session B

1:45–3:45 pm

Symposia

(S06) Pediatric Oncology in Developing Countries: How Can We Collaborate?

Moderator: Katherine K. Matthay, MD

ASPHO and the International Society of Pediatric Oncology (SIOP) are complementary organizations with a common mission to ensure that each child and young adult with cancer has access to state-of-the-art treatment by advancing research, education, care, and professional practice. Due to geographic, political, cultural, and economic barriers, children in economically disadvantaged countries often do not have sufficient access to care for malignancies. In addition, comorbidities contribute to poor survival. Although there is increasing interest in twinning and exposure of residents and faculty to work in low-income countries, there is lack of systematic coordination of these efforts. ASPHO and SIOP provide an opportunity to form new international collaborations in research and education and to aid the development of sustainable appropriate treatment protocols, education of physicians and medical staff, and supportive care. These global studies facilitate new insight into cancer epidemiology and biology and improve outcome for all through collaborative clinical trials.

Introduction of the Problem and SIOP Efforts, Foundations, and Academic Resources

Katherine K. Matthay, MD

Obstacles and Solutions to Access to Care in Oceania

Scott D. MacFarlane, MB ChB FRACP

Tools for Collaboration at a Distance

Scott C. Howard, MD

Establishing Support for Pediatric Oncology in Colombia: Dana-Farber Cancer Institute

Martha Vizcaino, MD

Friday, April 9, 2010 | *continued*

Impact of Twinning and International Support on Outcome of Children with Cancer in Morocco

Mhamed Harif, MD

(S07) Functional Genomics

Moderator: Sinisa Dovat, MD DSc

Functional genomics is a powerful tool for studying global changes in gene expression in health and disease. This technique is now widely available and feasible for routine use in clinical medicine. Recent studies have utilized functional genomics to characterize particular malignancies as well as define the genetic makeup that is associated with chemotherapy resistance. The aims of the symposium are to demonstrate how the use of functional genomics leads to a better understanding of the genetic basis of malignant disease and how the use of functional genomics can guide the clinician's decision about optimal chemotherapy for malignant diseases. Our goal is to present functional genomics as a tool for the future of personalized medicine.

Using High Throughput Genomics to Discover Drug-Resistance Pathways that Operate In Vivo

William L. Carroll, MD

Use of Functional Genomics to Design a Novel Targeted Therapy for Acute Promyelocytic Leukemia

Sinisa Dovat, MD DSc

Mapping the Genetic Basis of Gene Expression Networks

Christina Kendziorski, PhD

3:45–4:15 pm

Break with Exhibits and Posters

4:15–5:45 pm

Concurrent Workshops

(W04) Improving Outcomes for High-Risk ALL: Translating New Discoveries into Clinical Care

Moderator: Charles G. Mullighan, MD MBBS MSc FRACP FRCPA

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. Although great success has been achieved in ALL treatment, a substantial proportion of children with ALL are at high risk of treatment failure with existing therapy. In combination with traditional, but nonspecific, cytotoxic chemotherapy, agents targeting genetic alterations and pathways critical to leukemogenesis are showing great promise in improving chances for cure. These molecularly targeted agents often have favorable toxicity profiles due to their selectivity. This session will use a case-based approach to (1) introduce the need for new treatment approaches for high-risk ALL; (2) describe the use of genomic profiling that has identified novel targets for therapy in ALL; and (3) discuss the development of clinical trials that will examine the utility of novel therapies.

Overview on the Pathway from Identification of Lesions that Can Be Targeted to Clinical Trial Development Using Ph+ ALL as a Paradigm

Stephen P. Hunger, MD

Outcomes Following ALL Relapse and the Need for New Therapies

Elizabeth A. Raetz, MD

Genomics Initiatives in Childhood ALL

Charles G. Mullighan, MD MBBS MSc FRACP FRCPA

Development of Clinical Trials in High-Risk ALL

Mignon Loh, MD

(W05) Management of Very Young Children with Brain Tumors

Moderator: Murali M. Chintagumpala, MD

Brain tumors in very young children pose a considerable problem for management and cure. A greater proportion of these patients than older patients have disseminated disease. Often complete resections of tumors are not possible. The developing brain is highly susceptible to long-term injury due to surgery and radiation. To avoid radiation therapy, high-dose chemotherapy with bone marrow rescue has been recommended. This can lead to significant morbidity and mortality. Frequent and higher doses of systemic methotrexate along with intrathecal methotrexate, although effective, result in significant leukoencephalopathy. Focal radiation therapy along with chemotherapy is also effective in certain tumors. With the advent of proton beam radiation therapy there will likely be more indications for radiation therapy in these very young children. High-grade gliomas do not necessarily have a dismal outcome, as is the case in older children. Therefore, the biology of tumors in these children can provide fascinating insights.

Overview of Clinical and Management Challenges

Amar Gajjar, MD

Use of Radiation Therapy and the Potential Advantages of Proton Beam Radiation Therapy

Anita Mahajan, MD

6–7:30 pm

Business Meeting and Award Presentations

- ◆ President's Remarks
- ◆ Frank A. Oski Memorial Lecture
- ◆ Distinguished Career Award

7:45–8:15 pm

Award Reception

Educational Program | Saturday, April 10, 2010

7–8:30 am

Concurrent Workshops

(W06) Staging, Grouping, and Risk Assignment for Childhood Rhabdomyosarcoma

Moderator: Leo Mascarenhas, MD MS

Treatment of newly diagnosed children with rhabdomyosarcoma (RMS) is based on a fairly complex system of risk assignment that includes clinical staging and surgical grouping as well as histology. The clinical staging utilized is unique and utilizes a modified TNM staging that takes into account the location of the primary tumor. Additionally, certain sites require special staging considerations. There are 350–400 newly diagnosed patients with RMS occurring sporadically in the United States each year. Most pediatric oncologists treat very few patients with this diagnosis annually, thus making the task of risk assignment very challenging. There are also several misconceptions of risk assignment among pediatric oncologists, perhaps due to factors considered in other soft tissue sarcomas. This workshop will discuss best practices for risk assignment in an interactive session with case presentations and expert panel discussion on the management of these patients.

This workshop is supported by The Liddy Shriver Sarcoma Initiative and the Sarcoma Alliance.

Overview of Clinical Staging and Grouping with Brief Background

Leo Mascarenhas, MD MS

Histologic/Molecular Diagnosis and the Contribution of Subtypes to Prognosis

David M. Parham, MD

Risk Assignment in Childhood Rhabdomyosarcoma

Douglas S. Hawkins, MD

Case Presentations with Audience Participation and Expert Opinion

Chintan Parekh, MBBS

(W07) Career Development and Increasing Diversity in Pediatric Hematology/Oncology

Moderator: Kathleen M. Sakamoto, MD PhD

According to a recent analysis of ASPHO membership, 44% of members are women and 25% are minorities. Although medicine has become more diverse in recent decades, neither women nor minorities are represented in positions of leadership in academic medicine, including pediatric hematology/oncology, in proportions appropriate to their demographics within the profession as a whole.

For the field to thrive, it must benefit from the full leadership and academic potential of women and minorities. An understanding of the barriers to advancement and creative approaches to improving career success and leadership development is needed to ensure a dynamic, attractive, and thriving field.

The barriers, especially that involving work/life balance, are increasingly relevant to both men and women. Leaders of both genders must be mindful of the need to create gender balance in the workplace as they make hiring and search committee membership decisions.

Report on Survey from ASPHO Members

Judith F. Margolin, MD; Ernest Frugé, PhD

Diversity in the Workplace

Joan M. Lakoski, MD

Panel Discussion

Judy Felgenhauer, MD; Joanne M. Hilden, MD; Naomi L. C. Luban, MD; David G. Poplack, MD; Susan B. Shurin, MD; Anne E. Hagey, MD; Jeffrey M. Lipton, MD PhD

8:45–10:45 am

Symposia

(S08) Immunotherapy for Pediatric Cancer

Moderator: Nabil M. Ahmed, MD MSc

Despite the use of maximum multimodality approaches, including surgical resection, radical radiotherapy, and adjuvant chemotherapy, a number of pediatric malignancies remain largely incurable. This includes tumors that have an acceptable cure rate in the majority of patients at diagnosis but are metastatic or treatment resistant. It is now clear that maximization of conventional therapies has not translated into an appreciable survival advantage over the last 30 years in the aforementioned patients. Moreover, the toxicities of such salvage regimens are substantial. There is a pressing need for new targeted biologically based therapies for such diseases. Immunotherapies have the potential to fulfill this need because their high specificity should minimize toxicity to normal tissues, thereby reducing the long-term adverse effects endured by children with cancer. In this symposium, we will present recent advances in various immunotherapy modalities being developed to date.

Genetic Engineering of T Cell for Adoptive Transfer

Nabil M. Ahmed, MD MPH

Enhancing Immunity to Pediatric Cancers Using Vaccine-Based Approaches

Crystal L. Mackall, MD

Expansion and Genetic Modification of the Natural Killer Cells for Therapy of Cancer

Dario Campana, MD PhD

(S09) Thrombosis in Patients with Cancer

Moderator: Guy Young, MD

Thrombosis is a common complication occurring in children with cancer as a result of the frequent use of central venous catheters, the inherent hypercoagulability of cancer, the use of drugs which increase the risk for thrombosis, and immobilization, and other risk factors. There is emerging data regarding the epidemiology of thrombosis in cancer patients, which is important for both managing patients and addressing research questions. The major risk factor for thrombosis in cancer patients is the use of central venous catheters that are used almost universally. Thus, it is important to discuss catheter-related thrombosis, including separately examining the specific risk factors associated with the types of catheters, methods for placement, and duration of catheter placement. Lastly, the treatment of cancer patients with thrombosis has important implications related to the increased risk for bleeding due to thrombocytopenia or the tumor itself, the frequent need for procedures, and the multiple medications patients require.

Epidemiology of Thrombosis in Cancer Patients

Uma H. Athale, MD MSc FRCP

Epidemiology and Diagnosis of Catheter-Related Thrombosis in Cancer Patients

Janna M. Journeycake, MD MSCS

Management of Catheter-Related Thrombosis in Cancer Patients

Sarah Harvey O'Brien, MD MSc

Saturday, April 10, 2010 | *continued*

11:15 am–1:15 pm

Symposia

**(S10) Selecting Your Path and Taking the Critical First Steps
Toward a Successful Career** 

Moderator: Caroline A. Hastings, MD

The opening talk will compare and contrast the multiple career options available to young hematology/oncology specialists launching their careers. Various tracks and pathways lead to various career destinations—i.e., laboratory physician scientist, translational physician scientist, clinical physician scientist, “modern” or “traditional” clinical investigator, clinician, or clinician educator. Specific steps in each pathway regarding funding, timing, institutional resources required, and likelihood of success are highly variable and flexible depending on the personal and professional needs of each individual.

The second presentation will explore factors important in identifying the appropriate faculty position for the new junior faculty hematologist/oncologist. Strategies will be discussed for successfully negotiating the job contract necessary to help the junior faculty member succeed in the critical early years.

The final talk will provide guidance on how to navigate the junior faculty period with an emphasis on benchmarks and timelines for promotion and, equally as importantly, for building a satisfying career.

Career Development Pathways in Academic Medicine

George R. Buchanan, MD

**How to Find the Right Job and Negotiate the Contract You
Need to be Successful**

Joanne M. Hilden, MD

**Strategies for a Successful Career in Pediatric Hematology/
Oncology: What Is Next After Your Faculty Appointment?**

John M. Maris, MD

(S11) Biology of ALL

Moderator: Sinisa Dovat, MD DSc

The etiology and pathogenesis of one of the most common childhood malignancies—ALL—are not fully understood. Current chemotherapy regimens have led to improved survival of ALL patients, but chemotherapy-resistant ALL, as well as some subtypes of ALL (e.g., Ph+ ALL) remain a clinical challenge for treatment. During the last 5 years there have been tremendous advances in understanding the mechanisms of malignant transformation and control of proliferation of ALL. The purpose of the symposium is to present the newest advances in biology of ALL and discuss the potential use of these results in the design of novel, targeted chemotherapy for childhood ALL in order to improve the outcome of these patients.

Leukemia Stem Cells in B Cell Lineage ALL

Markus Muschen, MD

**Mer Receptor Tyrosine Kinase as a Novel ALL Therapeutic
Target**


Douglas K. Graham, MD PhD

**Ikaros as a Tumor Suppressor in Acute Lymphoblastic
Leukemia**

Sinisa Dovat, MD DSc

Posters

The 23rd Annual Meeting will feature two author-attended poster sessions. Chosen from a large number of submissions, the posters will represent the best innovations and research in the study and treatment of pediatric hematology/oncology. Poster abstracts selected for presentation at the Annual Meeting will be available online in a searchable database and in a *Pediatric Blood & Cancer* journal supplement. This will allow registrants to plan their poster viewing in advance of the meeting. The abstracts are scheduled to be available in March 2010. To search and view them, visit the annual meeting Web page at www.aspho.org.



Faculty

Thomas C. Abshire, MD
Aflac Cancer Center and Blood Disorders
Service
Atlanta, GA

Denise M. Adams, MD
Cincinnati Children's Hospital Medical Center
Cincinnati, OH

Nabil M. Ahmed, MD MSc
Texas Children's Hospital
Houston, TX

Blanche P. Alter, MD MPH FAAP
National Cancer Institute
Rockville, MD

Uma H. Athale, MD MSc FRCP
McMaster University
Hamilton, ON, Canada

Noreen M. Aziz, MD PhD MPH
National Cancer Institute
Bethesda, MD

Smita Bhatia, MD MPH
City of Hope National Medical Center
Duarte, CA

Amy L. Billett, MD
Dana-Farber Cancer Institute/
Children's Hospital Boston
Boston, MA

Victor S. Blanchette, MD FRCP(C)
Hospital for Sick Children
Toronto, ON, Canada

Susan M. Blaney, MD
Baylor College of Medicine
Houston, TX

Leonardo R. Brandao, MD
Hospital for Sick Children
Toronto, ON, Canada

H. James Brown, MD
American Board of Pediatrics
Chapel Hill, NC

George R. Buchanan, MD
University of Texas Southwestern Medical
Center at Dallas
Dallas, TX

Dario Campana, MD PhD
St. Jude Children's Research Hospital
Memphis, TN

Vern M. Campbell, MD FACS FRCS
St. Michael's Hospital
Toronto, ON, Canada

William L. Carroll, MD
New York University Medical Center
New York, NY

James F. Casella, MD
Johns Hopkins University School of
Medicine
Baltimore, MD

Jacqueline N. Casillas, MD MSHS
David Geffen School of Medicine at UCLA
Los Angeles, CA

Murali M. Chintagumpala, MD
Baylor College of Medicine
Houston, TX

George D. Demetri, MD
Dana-Farber Cancer Institute/Harvard
Medical School
Boston, MA

Jorge DiPaola, MD
The Children's Hospital
Aurora, CO

Sinisa Dovat, MD DSc
University of Wisconsin—Madison
Madison, WI

Noah Federman, MD
University of California—Los Angeles
Los Angeles, CA

Judy Felgenhauer, MD
Providence Sacred Heart Children's Hospital
Spokane, WA

Lewis R. First, MD MS
University of Vermont College of Medicine
Burlington, VT

Debra L. Friedman, MD MS
Vanderbilt-Ingram Cancer Center
Nashville, TN

Ernest Frugé, PhD
Baylor College of Medicine
Houston, TX

Amar Gajjar, MD
St. Jude Children's Research Hospital
Memphis, TN

Timothy P. Garrington, MD
The Children's Hospital
Aurora, CO

Douglas K. Graham, MD PhD
The Children's Hospital
Aurora, CO

Holcombe E. Grier, MD
Dana-Farber Cancer Institute
Boston, MA

Alejandro Gutierrez
Dana-Farber Cancer Institute
Boston, MA

Anne E. Hagey, MD
Hana Biosciences, Inc.
South San Francisco, CA

Mhamed Harif, MD
University Hospital Mohammed VI
Marrakech, Morocco

Caroline A. Hastings, MD
Children's Hospital of Oakland
Oakland, CA

Douglas S. Hawkins, MD
Seattle Children's Hospital
Seattle, WA

Joanne M. Hilden, MD
Peyton Manning Children's Hospital at
St. Vincent
Indianapolis, IN

Randy A. Hock, MD PhD CPE MMM
Riley Children's Hospital
Carmel, IN

W. Keith Hoots, MD
University of Texas MD
Anderson Cancer Center
Houston, TX

Scott C. Howard, MD
St. Jude Children's Research Hospital
Memphis, TN

Melissa M. Hudson, MD
St. Jude Children's Research Hospital
Memphis, TN

Stephen P. Hunger, MD
The Children's Hospital
Aurora, CO

Sara J. Israels, MD
University of Manitoba
Winnipeg, MB, Canada

Janna M. Journeycake, MD MSCS
University of Texas Southwestern Medical
Center at Dallas
Dallas, TX

Walter H. Kahr, MD PhD FRCP
Hospital for Sick Children
Toronto, ON, Canada

Ram Kalpatthi, MD
Medical University of South Carolina
Charleston, SC

Gregory J. Kato, MD
National Institutes of Health
Bethesda, MD

Christina Kendzioriski, PhD
University of Wisconsin—Madison
Madison, WI

Jennifer C. Kesselheim, MD MEd
Dana-Farber Cancer Institute
Boston, MA

Joan M. Lakoski, PhD
University of Pittsburgh Health Sciences
Pittsburgh, PA

Jeffrey M. Lipton, MD PhD
Schneider Children's Hospital
New Hyde Park, NY

Mignon Loh, MD
University of California—San Francisco
San Francisco, CA

Naomi L. C. Luban, MD
Children's National Medical Center
Washington, DC

**Scott D. Macfarlane, MB ChB
FRACP**
Starship Children's Hospital
Grafton, Auckland, New Zealand

Crystal L. Mackall, MD
National Institutes of Health
Bethesda, MD

Anita Mahajan, MD
University of Texas MD Anderson Cancer
Center
Houston, TX

Punam Malik, MD
Cincinnati Children's Hospital Medical Center
Cincinnati, OH

Kelly Maloney, MD
The Children's Hospital
Aurora, CO

Judith F. Margolin, MD
Baylor College of Medicine
Houston, TX

John M. Maris, MD
Children's Hospital of Philadelphia
Philadelphia, PA

Leo Mascarenhas, MD MS
Children's Hospital Los Angeles
Los Angeles, CA

Katherine K. Matthay, MD
University of California—San Francisco
San Francisco, CA

Dana C. Matthews, MD
Seattle Children's Hospital
Seattle, WA

Anna T. Meadows, MD
Children's Hospital of Philadelphia
Philadelphia, PA

Emily Riehm Meier, MD
Children's National Medical Center
Washington, DC

Paul V. Miles, MD
American Board of Pediatrics
Chapel Hill, NC

Brigitta U. Mueller, MD CPE MHCM
Baylor College of Medicine
Houston, TX

**Charles G. Mullighan, MD MBBS
MSc FRACP FRCPA**
St. Jude Children's Research Hospital
Memphis, TN

Markus Muschen, MD
Children's Hospital Los Angeles
Los Angeles, CA

Jospeh P. Neglia, MD MPH
University of Minnesota
Minneapolis, MN

Sarah Harvey O'Brien, MD MSc
The Research Institute at Nationwide
Children's Hospital
Columbus, OH

Alberto S. Pappo, MD
Texas Children's Cancer Center
Houston, TX

Chintan Parekh, MBBS
Children's Hospital Los Angeles
Los Angeles, CA

David M. Parham, MD
University of Oklahoma
Oklahoma City, OK

David G. Poplack, MD
Texas Children's Cancer Center
Houston, TX

Charles T. Quinn, MD MS
University of Texas Southwestern Medical
Center at Dallas
Dallas, TX

Elizabeth A. Raetz, MD
NYU School of Medicine
New York, NY

Leslie Raffini, MD MSCE
Children's Hospital of Philadelphia
Philadelphia, PA

Christopher J. Recklitis, PhD MPH
Dana-Farber Cancer Institute
Boston, MA

A. Kim Ritchey, MD
Children's Hospital of Pittsburgh
Pittsburgh, PA

Georges E. Rivard, MD
University of Montréal
Montréal, QC, Canada

Zora R. Rogers, MD
University of Texas Southwestern Medical
Center
Dallas, TX

Kathleen M. Sakamoto, MD PhD
David Geffen School of Medicine at UCLA
Los Angeles, CA

Lisa A. Schwartz, PhD
Children's Hospital of Philadelphia
Philadelphia, PA

Susan B. Shurin, MD
National Institutes of Health
Bethesda, MD

Poul Sorensen, MD PhD
University of British Columbia
Vancouver, BC, Canada

Michael J. Temple, MD
Hospital for Sick Children
Toronto, ON, Canada

Sarah R. Vaiselbuh, MD
Schneider Children's Hospital
New Hyde Park, NY

Elliott P. Vichinsky, MD
Children's Hospital & Research Center
Oakland
Oakland, CA

Martha Vizcaino, MD
Instituto Nacional de Cancerología
Bogotá, Colombia

Daniel S. Wechsler, MD PhD
Duke University Medical Center
Durham, NC

David A. Williams, MD
Children's Hospital Boston/
Harvard Medical School
Boston, MA

Darrell J. Yamashiro, MD PhD
Columbia University Medical Center
New York, NY

Guy Young, MD
Children's Hospital Los Angeles
Los Angeles, CA

**Patrick A. Zweidler-McKay, MD
PhD**
University of Texas MD Anderson Cancer
Center
Houston, TX

ASPHO Thanks Our 2010
Corporate Members and Gold-Level Supporters

GRIFOLS

NOVARTIS

novo nordisk®

Corporate Forum Symposia

Independently sponsored corporate forum symposia are offered in conjunction with the ASPHO 23rd Annual Meeting. The programs have been reviewed and approved by the 2010 ASPHO Program Committee to ensure they are relevant to the audience and that they do not duplicate the official ASPHO program.

These satellite symposia are open to registrants of the 2010 Annual Meeting at no additional charge, although preregistration is required. See the registration details for each symposium below. Seating is available to those responding on a first-come, first-served basis.

Wednesday, April 7, 2010

7:30–9 pm

Corporate Forum Dinner Symposium

Contemporary Challenges in the Diagnosis and Management of von Willebrand's Disease

Robert R. Montgomery, MD; Augusto B. Federici, MD; Andra H. James, MD; Craig M. Kessler, MD

This symposium will consider unresolved issues in the diagnosis and management of von Willebrand's disease. After addressing the specific quantitative and qualitative deficiencies of the von Willebrand factor on which classification is based and approaches to treatment generally defined, the program will explore diagnostic and management challenges confronting the pediatric hematologist.

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Cincinnati designates this activity for a maximum of **1.5 AMA PRA Category 1 Credits™**. Physicians should only claim credits commensurate with the extent of their participation in the activity.

This symposium is supported through an educational grant from Grifols USA, LLC.

To preregister for this event, please visit www.thrombo.net/aspho.

Thursday, April 8, 2010

12:30–2 pm

Corporate Forum Lunch Symposium

Perspectives in Hemophilia: Clinical Challenges and Current Issues in Managing Patients with Inhibitors

Amy D. Shapiro, MD; Victor S. Blanchette, MD FRCP FRCP(C); Michael Recht, MD PhD

Clinicians who treat hemophilia A patients with inhibitors routinely encounter several clinical challenges when developing appropriate patient management strategies. This symposium will provide a provocative perspective on these important challenges and offer expert commentary addressing issues on clinical data, various therapeutic regimens, joint health, and health-related quality of life.

This activity will be planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM), the Cardiovascular and Metabolic Health Foundation, and Educational Concepts in Medicine. PIM is accredited by the ACCME to provide continuing medical education for physicians.

PIM designates this activity for a maximum of **1.5 AMA PRA Category 1 Credits™**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This symposium is supported through an educational grant from Novo Nordisk, Inc.

Please visit us at www.bloodcmecenter.org to learn more about this event and to access additional CME programs on blood disorders.

Thursday, April 8, 2010

7:30–9 pm

Corporate Forum Dinner Symposium

Optimizing Chelation Therapy for Pediatric Iron Overload: Emerging Strategies

Elliott P. Vichinsky, MD; Nancy F. Olivieri, MD BSc FRCPC; John B. Porter, MD MA FRCP FRCPATH; John C. Wood, MD PhD

Iron overload is a disorder characterized by the accumulation of excess iron in bodily tissues. It can be caused by hemochromatosis or may be a complication of frequent, regular blood transfusions used to treat severe anemia in patients with sickle cell disease (SCD), thalassemia, and other hematologic malignancies. If left untreated, iron accumulation in organs such as the liver, heart, and pancreas can cause organ failure and early death. Identifying a therapeutic strategy that is safely compatible with coexisting medical conditions and provides effective management of iron burden is an important aspect of treatment for iron overload, as it may be necessary to initiate therapy in patients as young as 2 years of age. One strategy that can be used to decrease and manage body iron levels in pediatric patients is iron chelation therapy. Ongoing development of new agents for iron chelation therapy and techniques for the detection of body iron stores is continuing to increase survival and improve quality of life for pediatric patients experiencing iron overload. At the end of this activity, participants will be able to describe the etiology, risk factors, and consequences of iron overload, evaluate the safety and efficacy of iron chelation therapy, and summarize the efficacies of available techniques for monitoring iron overload in pediatric patients.

The Center for Biomedical Continuing Education™ (CBCE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CBCE™ designates this activity for a maximum of **1.5 AMA PRA Category 1 Credits™**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This symposium is supported through an educational grant from Novartis Oncology.

To preregister for this event, please visit www.thebce.com and click on "upcoming events."

Exhibit Schedule

Thursday, April 8

Exhibit Setup and Exhibitor Registration 8 am–4 pm
Grand Opening Reception with
Exhibits and Posters 5:45–7:30 pm

Friday, April 9

Exhibits Open 10:30 am–4:15 pm
Break with Exhibits
and Posters 10:45–11:15 am, 12:30–1:45 pm, 3:45–4:15 pm
Exhibit Teardown 4:15–7 pm

Join ASPHO to enjoy discounted registration fees

aspho Membership Application

Please complete this form and provide all information requested.

Have your application signed by a current member of ASPHO (see below).

If you are a trainee, you must provide a letter of recommendation from your training program director.

General Information (Please print or type.)

The following information is required to complete your application process.

Name _____ Degree(s) _____

Title/Department _____

The following information is *required*. Only professional affiliation and address information will be published in the Member Directory.

Facility/Hospital or University _____

Facility Address _____

City/State/ZIP _____

Office Phone _____

Office Fax _____

E-mail Address _____

Preferred mailing address: Office (as above) Home

If you prefer to receive ASPHO mailings at home, please provide your home address.

Home Address _____

Home City/State/ZIP _____

Membership Categories and Annual Dues

Select the category of membership for which you are applying.
See descriptions online at www.aspho.org.

Active Member* \$335

Affiliate Member*

Without optional Journal \$50

With optional Journal \$75

**Membership applications must be endorsed and signed by a current member of ASPHO.*

Trainee Member**

First-Year Fellow No charge

Second-Year Fellow No charge

Third-Year Fellow No charge

Fourth-Year Fellow \$115

Fifth-Year Fellow \$115

***Applicants for trainee membership must provide a letter of recommendation from their training program director. Please include this recommendation with your application.*

I recommend this individual for membership in ASPHO.

Member Name (please print) _____

Member Signature _____ Date _____

Form Submission

Submit the completed application and payment with ASPHO 2010 Annual Meeting registration form.
Questions? Please call ASPHO's Member Services department at 847/375-4716.

Hotel

ASPHO has selected the Fairmont The Queen Elizabeth as the headquarters hotel. A special rate has been negotiated for a number of rooms at this hotel. This special rate expires March 1, 2010, or when the negotiated room block has been filled. After that time, higher rates may apply.

Fairmont The Queen Elizabeth

900 Rene Levesque Blvd. West
Montréal, Québec, Canada H3B4A5
Rate: \$189 CAD single/double
Cutoff Date: March 1, 2010
Reservations: 800/441-1414
www.aspho.org

President's Club

Fairmont Hotels has a loyalty program for its guests. The President's Club offers many rewards including daily in-room **complimentary Internet access**, daily paper, health club access, and more. The program is free but does require registration before first night of the stay. For more information, visit www.fairmont.com/fpc/.

Montréal Information

Montréal is home to more than 3 million people, making it the second largest city in Canada. The city is easy to travel into and get around. Public transportation is widely available and recommended to avoid the hustle of the city. Montréal is also home to more than 200 miles of bike paths connecting many major tourist hubs. Visit Parc Jean-Drapeau to see the site of the 1967 World's Fair, which is now home to Montréal Biosphere. The Biosphere contains a museum dedicated to the Canadian environment. Montréal is additionally known as a cultural hub and home to many theaters and exhibits. For more information, visit www.tourisme-montreal.org.

Passport Information

In recent years, the laws have changed regarding travel across national borders. To travel into Canada you will need a valid passport. Effective June 1, 2009, the United States will require anyone entering from Canada, by land or air, to have a valid passport. For more information on traveling to or from Canada, visit www.consular.canada.usembassy.gov.

Airline

UNITED is offering special meeting discounts for attendees of the ASPHO meeting. Simply call (or have your travel agent call) our Special Meeting Desk at 800/521-4041 and refer to Meeting ID Number 550KO to receive a 2%–15% discount off applicable fares. If you purchase your ticket at least 30 days prior to travel, you will receive an additional 5% discount (on most classes of service). This special offer applies to travel on domestic segments of all United Airlines, United Express, TED and United code share flights (UA*) operated by US Airways, US Airways Express, and Air Canada.

To purchase your ticket online, visit www.united.com and receive a 5% discount off the lowest applicable fares. After you link to www.united.com, enter your origin and destination, travel dates, and your promotion code number 550KO; available flights will then be displayed. Flights that qualify for the discount will be clearly identified with a red star symbol, which means that the itinerary is "electronic certificate eligible." When you select an electronic certificate eligible flight, United will automatically calculate and present your discounted fare. This special offer applies to flights to or from the US only. There are no fees for booking on line. Note the Code 550KO is case sensitive and the characters need to be capitalized.

To check schedules and to take advantage of this offer, please visit www.united.com or call 800/521-4041.

Handout Materials

Registrants can access and view handout materials online. ASPHO will not print a paper syllabus of speakers' handouts. ASPHO is excited to offer annual meeting attendees complimentary online access to the audio recordings and slide presentations of speakers' lectures from the meeting. After the meeting, the recordings will be available on the ASPHO Web site beginning in May 2010. Meeting registrants will receive an e-mail in May with a unique password and instructions about how to access the online recordings.

Program Committee

Judith F. Margolin, MD, Chair

Baylor College of Medicine
Houston, TX

Jorge DiPaola, MD, Vice Chair

The Children's Hospital
Aurora, CO

Guy Young, MD, Past Chair

Childrens Hospital Los Angeles
Los Angeles, CA

Denise M. Adams, MD

Cincinnati Children's Hospital Medical
Center
Cincinnati, OH

George R. Buchanan, MD

University of Texas Southwestern
Medical Center at Dallas
Dallas, TX

Jacqueline N. Casillas, MD MSHS

David Geffen School of Medicine at
UCLA
Los Angeles, CA

Murali M. Chintagumpala, MD

Baylor College of Medicine
Houston, TX

Sinisa Dovat, MD DSc

University of Wisconsin–Madison
Madison, WI

Douglas K. Graham, MD PhD

The Children's Hospital, Denver
Aurora, CO

Sumit Gupta, MD

Hospital for Sick Children
Toronto, Ontario, Canada

Caroline A. Hastings, MD

Children's Hospital of Oakland
Oakland, CA

Leo Mascarenhas, MD MS

Childrens Hospital Los Angeles
Los Angeles, CA

Zora R. Rogers, MD

University of Texas Southwestern
Medical Center at Dallas
Dallas, TX

Leonard A. Valentino, MD

Rush University Medical Center
Chicago, IL

Daniel S. Wechsler, MD PhD

Duke University Medical Center
Durham, NC

Donald L. Yee, MD

Baylor College of Medicine
Houston, TX

Peter Zage, MD PhD

MD Anderson Cancer Center
Houston, TX



ASPHO 2010 Annual Meeting Registration Form

April 7–10, 2010 | Fairmont the Queen Elizabeth Hotel | Montréal, QC, Canada

FOR OFFICE USE ONLY

Cust # _____ Mtg Ord #3- _____

Date _____

Please print. Use a separate form for each registrant. Duplicate as necessary.

Complete Name _____ First Name for Badge _____

Facility _____ Facility City/State _____

Preferred Address (Home Office) _____ City/State/ZIP _____

Home Phone _____ Office Phone _____ Fax _____

E-mail* (required) (Home Office) _____ (FTA) Check here if this will be your first ASPHO Conference.

Emergency Contact Name _____ Day Phone _____ Evening Phone _____

*You will receive an e-mail confirmation of your registration when it has been processed.

To register, make your selections in the boxes below, add the subtotals, and indicate the total amount in box F.

Conference Registration		A	
Member Rates	On or before 2/23/10	After 2/23/10	
Regular Member (M)	<input type="checkbox"/> \$450	<input type="checkbox"/> \$525	
Affiliate Member (MA)	<input type="checkbox"/> \$275	<input type="checkbox"/> \$350	
Trainee Member (MT)	<input type="checkbox"/> \$150	<input type="checkbox"/> \$225	
Emeritus Member (ME)	<input type="checkbox"/> \$150	<input type="checkbox"/> \$225	
Join & Register Rates (add dues in box B)			
<i>You must complete and return the membership application on page 13, including any required endorsements or letters of recommendation with your registration form.</i>			
Active Member (JR)	<input type="checkbox"/> \$450 plus dues	<input type="checkbox"/> \$525 plus dues	
Affiliate Member (JRA)	<input type="checkbox"/> \$275 plus dues	<input type="checkbox"/> \$350 plus dues	
Trainee Member (JRT)	<input type="checkbox"/> \$150 plus dues	<input type="checkbox"/> \$225 plus dues	
Nonmember Rates			
Nonmember (N)	<input type="checkbox"/> \$625	<input type="checkbox"/> \$700	
Affiliate Nonmember (NA)	<input type="checkbox"/> \$325	<input type="checkbox"/> \$400	
Trainee Nonmember (NT)	<input type="checkbox"/> \$200	<input type="checkbox"/> \$275	
		Subtotal A \$ _____	

Session Registration		D	
<i>Please note the following workshops you plan to attend. See page 3 for session codes.</i>			
Wednesday, April 7		Friday, April 9	
2–5:30 pm	<input type="checkbox"/> I <input type="checkbox"/> D <input type="checkbox"/> S	8:45–10:45 am	<input type="checkbox"/> S <input type="checkbox"/> O
5:45–7:15 pm	<input type="checkbox"/> W <input type="checkbox"/> O	1:45–3:45 pm	<input type="checkbox"/> S <input type="checkbox"/> O
Thursday, April 8		4:15–5:45 pm	
7–8:30 am	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> W <input type="checkbox"/> O	
2:15–4:15 pm		Saturday, April 10	
<input type="checkbox"/> S <input type="checkbox"/> O		7–8:30 am	<input type="checkbox"/> W <input type="checkbox"/> O
		8:45–10:45 am	<input type="checkbox"/> S <input type="checkbox"/> O
		11:15 am–1:15 pm	<input type="checkbox"/> S <input type="checkbox"/> O

Optional Event Registration		E	
Thursday, April 8			
12:30–2 pm One-on-One Young Investigator Career Lunch Workshop* \$15			
<i>(Limited to the first 80 registrants)</i>			
Please select one topic for your table assignment:			
<input type="checkbox"/> Basic Science/Translational Research (LBT)	<input type="checkbox"/> Clinical Research-Hematology (LCH)		
<input type="checkbox"/> Clinical Research-Oncology (LCO)	<input type="checkbox"/> Health Services Late Effects (LCS)		
<input type="checkbox"/> Clinician/Educator (LCE)			
<input type="checkbox"/> Foreign Medical Graduates (FMG)			
* Attendance limited to Young Investigators only.			
			Subtotal E \$ _____

Membership Dues		B	
Active Member	<input type="checkbox"/> \$335	Trainee Member	
Affiliate Member		First-year fellow	<input type="checkbox"/> no charge
Without optional journal	<input type="checkbox"/> \$50	Second-year fellow	<input type="checkbox"/> no charge
With optional journal	<input type="checkbox"/> \$75	Third-year fellow	<input type="checkbox"/> no charge
<i>You must complete and return the membership application on page 13, including any required endorsements or letters of recommendation with your registration form.</i>		Fourth-year fellow	<input type="checkbox"/> \$115
		Fifth-year fellow	<input type="checkbox"/> \$115
		Subtotal B \$ _____	

4 easy ways to register	
Mail	ASPHO Meeting • PO Box 839 • Glenview, IL 60025-0839
Phone*	847/375-4716
Fax*	866/585-0477
Online*	www.aspho.org
*credit card payment only	

Special Requests		C	
<input type="checkbox"/>	I will require special assistance. (SA)		
<input type="checkbox"/>	I will need a vegetarian meal. (SDV)		
<input type="checkbox"/>	I do not wish to have my name and contact information included in the on-site attendee list. (DIS)		

Cancellation Policy: All cancellations must be made in writing. A \$100 processing fee will be charged for all cancellations postmarked more than 14 days before the event. No refunds will be made under any circumstances on cancellations postmarked after March 24, 2010. ASPHO reserves the right to substitute faculty or to cancel or reschedule sessions due to low enrollment or other unforeseen circumstances. If ASPHO must cancel the entire meeting, registrants will receive a full credit or refund of their paid registration fee. No refunds can be made for lodging, airfare, or any other expenses related to attending the meeting.

(A + B + E) = \$ _____ **Total** F

Payment	
All funds must be submitted in U.S. dollars.	
<input type="checkbox"/>	Visa <input type="checkbox"/> Mastercard <input type="checkbox"/> Discover <input type="checkbox"/> American Express <input type="checkbox"/> Check
If payment does not accompany this form, your registration will not be processed.	
<ul style="list-style-type: none"> • Make checks payable to ASPHO. Checks not in U.S. funds will be returned. • A charge of \$50 will apply to checks returned for insufficient funds. • If rebilling of a credit card charge is necessary, a \$75 processing fee will be charged. • I authorize ASPHO to charge the above-listed credit card amounts reasonably deemed by ASPHO to be accurate and appropriate. 	
Account Number _____	Exp. Date _____
Cardholder's name (print) _____	Signature _____

Don't Miss the 2010 ASPHO 23rd Annual Meeting

April 7–10, 2010, Montréal, Québec, Canada

- ◆ Expanded Young Investigator program
- ◆ Seven new workshops
- ◆ Special session on your role as medical educator
- ◆ Original science abstract platform sessions
- ◆ Special session on maintenance of certification
- ◆ Charming cosmopolitan locale known for its festivals, fine dining, and nightlife.

